The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.
Thazhath, Sony S., Marathe, Chinmay S., Wu, Tongzhi, Chang, Jessica, Khoo, Joan, Kuo, Paul, Checklin, Helen L., Bound, Michelle J., Rigda, Rachael S., Crouch, Benjamin, Jones, Karen L., Horowitz, MichLanguage:
english
Journal:
Diabetes
DOI:
10.2337/db15-0893
Date:
October, 2015
File:
PDF, 537 KB
english, 2015